Bifogade filer
PDF
Kurs
+2,07%
Kurs
+2,07%
Open
147,20
High
150,00
Low
142,00
Close
148,00
Kursutveckling under dagen för detta pressmeddelande
(SEK).
Likviditet
22,9 MSEK
Likviditet
22,9 MSEK
Rel. mcap
0,11%
Antal aktier
156 337
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2027-01-28 | 08:00 | Bokslutskommuniké 2026 |
| 2026-10-22 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-16 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-06 | N/A | Årsstämma |
| 2026-04-23 | 08:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-03 | 08:00 | Bokslutskommuniké 2025 |
| 2025-10-23 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | - | Kvartalsrapport 2025-Q2 |
| 2025-04-30 | - | X-dag ordinarie utdelning VITR 1.10 SEK |
| 2025-04-29 | - | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-01-30 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-02 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
| 2023-04-27 | - | Årsstämma |
| 2023-04-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
| 2022-04-27 | - | Årsstämma |
| 2022-04-22 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-16 | - | X-dag ordinarie utdelning VITR 0.00 SEK |
| 2020-06-15 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-11-06 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-03 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
| 2019-05-02 | - | Årsstämma |
| 2019-04-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-11-06 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-13 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | Split VITR 1:5 |
| 2018-04-27 | - | X-dag ordinarie utdelning VITR 3.70 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-08 | - | Bokslutskommuniké 2017 |
| 2017-11-02 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-14 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | X-dag ordinarie utdelning VITR 2.60 SEK |
| 2017-04-27 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-03 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-20 | - | Kapitalmarknadsdag 2016 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | X-dag ordinarie utdelning VITR 2.40 SEK |
| 2016-04-28 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-05 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-14 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-06 | - | X-dag ordinarie utdelning VITR 1.50 SEK |
| 2015-05-05 | - | Årsstämma |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-06 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Analytiker möte 2014 |
| 2014-11-06 | - | Kapitalmarknadsdag 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-11 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
| 2014-05-05 | - | Årsstämma |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-11-11 | - | Kapitalmarknadsdag 2013 |
| 2013-11-07 | - | Analytiker möte 2013 |
| 2013-11-07 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-12 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-30 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2013-04-29 | - | Årsstämma |
| 2013-04-19 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-07 | - | Bokslutskommuniké 2012 |
| 2012-11-01 | - | Analytiker möte 2012 |
| 2012-11-01 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-24 | - | Extra Bolagsstämma 2012 |
| 2012-07-13 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-20 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2012-04-19 | - | Årsstämma |
| 2012-04-19 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-07 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-14 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2011-04-27 | - | Årsstämma |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-09 | - | Bokslutskommuniké 2010 |
| 2010-11-02 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-15 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-27 | - | X-dag ordinarie utdelning VITR 0.50 SEK |
| 2010-04-27 | - | Kvartalsrapport 2010-Q1 |
| 2010-04-26 | - | Årsstämma |
| 2010-02-05 | - | Bokslutskommuniké 2009 |
| 2009-11-03 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-15 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-28 | - | X-dag ordinarie utdelning VITR 0.40 SEK |
| 2009-04-27 | - | Årsstämma |
| 2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-10-23 08:00:00
Third quarter
- Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local currencies excluding discontinued business* was 5%.
- Sales per region, in local currencies, were -2% in EMEA, +4% excluding discontinued business, +11% in Americas and +1% in APAC.
- Sales per product group, in local currencies excluding discontinued business, were +7 in Consumables, +8% in Technologies and +3% in Genetics.
- Sales per product group, in local currencies, were +4% in Consumables, +8% in Technologies and 0% in Genetics.
- Gross margin increased to 58.9% (58.6), explained by a favourable product mix despite negative currency impact.
- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 253 (289) million, resulting in an EBITDA margin of 30.3% (33.4), impacted by negative currency effect.
- Operating cash flow amounted to SEK 255 (206) million.
- Net income amounted to SEK 102 (116) million, resulting in earnings per share of SEK 0.75 (0.85).
First nine months
- Sales of SEK 2,548 (2,650) million, 1% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -5%. Organic growth in local currencies excluding discontinued business was 4%.
- Sales per region, in local currencies, were +1% in EMEA, +8% excluding discontinued business, +8% in Americas and -5% in APAC.
- Sales per product group, in local currencies excluding discontinued business, were +7% in Consumables, -1% in Technologies and +3% in Genetics.
- Sales per product group, in local currencies, were +4% in Consumables, -2% in Technologies and +1% in Genetics.
- Gross margin decreased to 58.1% (58.6) negatively impacted by currency.
- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 753 (888) million, resulting in an EBITDA margin of 29.5% (33.5), significantly impacted by negative currency effect.
- Operating cash flow amounted to SEK 475 (640) million.
- Net income amounted to SEK 301 (375) million, resulting in earnings per share of SEK 2.23 (2.76).
Gothenburg, October 23, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
* Discontinued business refers to discontinued activities in certain markets in EMEA.
The information was submitted for publication, through the agency of the contact persons set out above, at "Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">"Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">23-10-2025 08:00 CET.
Contact:
Amelie Wilson, Investor relations, external corporate communications and executive support, awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.